A new Boston University School of Medicine study has found that low-income and minority parents may be more receptive to vaccinating their daughters against Human Papillomavirus, while white, middle-class parents are more likely to defer the vaccination.
[More]
A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein.
[More]
Researchers at Weill Cornell Medical College have successfully tested their novel anti-cocaine vaccine in primates, bringing them closer to launching human clinical trials.
[More]
The HPV vaccine can prevent both cervical cancer and a nasty sexually transmitted disease in women.
[More]
In Kenya, women face a cervical cancer mortality rate that is approximately 10 times as high as in the United States.
[More]
A clinical study reporting an association between the results of the ChemoFx chemoresponse assay and recurrence free survival of cervical cancer patients has been accepted for publication by Gynecologic Oncology.
[More]
BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase I/II trial for BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus.
[More]
Rates of premature mortality in the UK have been falling steadily, but the pace of decline is not as fast as in many other high-income countries, such as Australia. In that sense, the UK lags behind.
[More]
A new drug is offering dramatic cure rates for hepatitis C patients with two subtypes of the infection -- genotype 2 and 3, say a team of scientists led by Weill Cornell Medical College researchers.
[More]
Two large, landmark radiotherapy studies have shown that it is possible to treat cervical cancer effectively with high doses specifically adapted to each tumour, and with fewer serious side-effects to the surrounding normal organs.
[More]
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the first patient has been dosed in a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer coordinated by the Brown University Oncology Research Group (BrUOG).
[More]
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has entered into a Memorandum of Understanding (MoU) with FusionVax, Inc. ("FusionVax") setting forth the main terms under which Advaxis will, subject to the entry of a definitive agreement, exclusively license its lead clinical stage product candidate, ADXS-HPV, to FusionVax for Asia.
[More]
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company's lead clinical stage product candidate, have been selected for poster presentation at the 2013 American Society of Clinical Oncology Annual Meeting in Chicago, IL, from May 31 - June 4, 2013, at the McCormick Place Convention Center.
[More]
BGI Health and ACIBADEM Healthcare Group Genetic Diagnostic Center in cooperation with Genoks Company Molecular Biology, signed a Memorandum of Understanding for jointly introducing the advanced genetic testing technologies to Turkey and improving Turkish reproductive healthcare.
[More]
New discoveries by a team of scientists at LSU Health Sciences Center New Orleans for the first time reveal the inner workings of a master regulator that controls functions as diverse as the ability of nerve cells to "rewire" themselves in response to external stimuli and the mechanism by which certain viruses hijack normal cellular processes to facilitate their replication that can ultimately lead to cancer. The research will be published in the April 12, 2013 issue of the Journal of Biological Chemistry.
[More]
There are over 100 different types of human papilloma virus (HPV). Cervical cancer is known to be caused by infection with approximately 14 so-called "high-risk" types of this virus.
[More]
An annual report from the American Cancer Society finds continuing challenges in changing behaviors and risk factors in order to reduce suffering and death from cancer.
[More]
BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.
[More]
Weill Cornell Medical College has established the new Feil Family Brain and Mind Research Institute, a unique, multidisciplinary translational neuroscience research hub. Named in honor of long-time benefactors Gertrude and Louis Feil, the institute was created with a generous $28 million gift from the Feil Family.
[More]
The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 175 national research and training grants totaling $79,073,250 for fiscal year 2013.
[More]